title: High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist.
abstract: High daily doses of gonadotrophin-releasing hormone (GnRH) antagonists during the follicular phase of ovarian stimulation were associated with low implantation rates. To test if this occurred because of profound pituitary suppression, the pituitary response was suppressed with a high-dose GnRH antagonist and recombinant LH (rLH) was added back to correct the implantation rate. An open-label, randomized, controlled, prospective clinical study in 60 patients undergoing IVF was performed. GnRH antagonist was initiated on day 6 of stimulation (2 mg/day) together with 375 IU rLH, and maintained until the day of HCG administration. Controls received 0.25 mg/day GnRH antagonist. Fluctuating LH concentrations were present on days 3 and 6 in both groups. This strong fluctuation continued on day 8 and on the day of HCG administration in the control (low-dose) group, where 30% of patients had LH concentrations <1 IU/l on the HCG day. The study (high-dose) group showed stable LH concentrations on day 8 and on the HCG day, with no LH surges. No clinical differences were found between groups. The LH add-back strategy (375 IU/day) rescued the adverse effects that high doses of GnRH imposed on implantation. These results suggest that rLH should be considered during ovarian stimulation with GnRH antagonist.
authors.affiliation: Instituto Valenciano de Infertilidad Madrid, Madrid, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Garcia-Velasco
authors.forename: H J T
authors.initials: HJ
authors.lastname: Coelingh Bennink
authors.forename: R
authors.initials: R
authors.lastname: Epifanio
authors.forename: E
authors.initials: E
authors.lastname: Escudero
authors.forename: A
authors.initials: A
authors.lastname: Pellicer
authors.forename: C
authors.initials: C
authors.lastname: Simón
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D007986:Luteinizing Hormone / Q000235:genetics / Q000627:therapeutic use*; D010062:Ovulation Induction; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone